Amneal and Impax create diversified pharmaceutical company
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc.
Pharmacy
Praxbind, specific reversal agent for Pradaxa, available nationwide
Boehringer Ingelheim announced that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states.
Camber launches generic Opana
PISCATAWAY, N.J. – Camber Pharmaceuticals is pleased to announce the addition of oxymorphone tablets to our growing portfolio of products. Oxymorphone tablets are the generic version of Opana from Endo Pharmaceuticals and is used to treat moderate to severe pain.
NACDS’ thought leadership on display at World Health Care Congress
WASHINGTON – The role of National Association of Chain Drug Stores members in the conversation about improving healthcare and addressing related societal challenges was on display during the 15th Annual World Health Care Congress, held earlier this week here.
Upsher-Smith releases Doxazosin tablets
Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018.
Amneal launches generic for Sabril
Amneal Pharmaceuticals has launched vigabatrin for oral solution USP, a generic equivalent for Sabril. This is the second generic vigabatrin product currently on the market. Each carton contains fifty 500 mg packets. The finished dosage form is manufactured in the United States.
Walgreens joins pioneering health science project
A nationwide consortium led by the National Institutes of Health (NIH) will launch the All of Us Research Program on Friday, May 6, which is being hailed as a pioneering research initiative that will use advance technologies and engage participants as citizen-scientists to embark on a new era of hea
Diplomat launches CastiaRx, leading specialty benefit manager
Diplomat Pharmacy has unveiled CastiaRx to respond to industry demand for a leader in specialty benefit management.
Camber Pharmaceuticals launches generic Methylin
ADHD. Methylphenidate chewable tablets are available in 2.5, 5 and 10mg 100 count bottles. The
Rexall to shutter 40 stores
McKesson Canada’s Rexall chain is closing 40 outlets in Ontario and Western Canada, nearly one-tenth of its total store base, according to a memo sent to company employees. The closings come about a year and a half after San Francisco-based McKesson Corp. finalized the purchase of Rexall Health.
NACDS welcomes House drug disposal bill
ARLINGTON, Va. – On the day before National Prescription Drug Take Back Day, the National Association of Chain Drug Stores today thanked the lead U.S. House of Representatives sponsors of H.R.
AllianceRx Walgreens Prime and Walgreens gain access to more specialty drugs
AllianceRx Walgreens Prime, the combined central specialty and home delivery pharmacy formed by Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), and Walgreens, announce the availability of several new limited distribution drugs for its specialty patients.
Foundation to offer opioid resource grants
The AmerisourceBergen Foundation has launched a new grant program broadening its efforts to curb opioid abuse.
NACDS applauds Senate letter on TRICARE pharmacy access
The National Association of Chain Drug Stores today thanked U.S. Senators Michael Rounds (R, S.D.) and Gary Peters (D, Mich.) for their leadership in sending a bipartisan letter to the Department of Defense’s (DoD) Robert Wilkie, undersecretary for personnel and readiness.
CVS: committed to safe medication disposal
CVS Health today underscored its commitment to helping communities safely dispose of unwanted medications, particularly as an important step in helping to address and prevent opioid abuse and misuse.
Aurobindo receives FDA approval for capecitabine tablets
Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for capecitabine tablets USP, 150 mg, and 500 mg. Aurobindo’s capecitabine tablets USP are an AB-rated generic equivalent to the reference listed drug Xeloda.